Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium in Early Stage COPD
NCT03842839Completed
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Aug 2019
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tiotropium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoint: Change from baseline in inner luminal area (Ai) of small airways (7th to 9th generation bronchi) at 24 months. Started Aug 2019; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03842839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842839.